



Published in final edited form as:

*Mutat Res.* 2004 March 22; 547(1-2): 123–132. doi:10.1016/j.mrfmmm.2003.12.010.

## Enhanced stimulation of chromosomal translocations by radiomimetic DNA damaging agents and camptothecin in *Saccharomyces cerevisiae rad9* checkpoint mutants

Michael Fasullo<sup>\*</sup>,

Li Zeng,

Peter Giallanza

Ordway Research Institute, The Albany Medical College, 150 New Scotland Ave., Albany, NY 12208, USA

### Abstract

*Saccharomyces cerevisiae rad9* checkpoint mutants exhibit pleiotropic phenotypes, including higher frequencies of chromosome loss, radiation sensitivity, and decreased induction of DNA damage-inducible genes. We had previously shown that *rad9* mutants exhibit higher frequencies of DNA damage-associated translocations but lower frequencies of DNA damage-associated sister chromatid exchange (SCE), compared to wild type. Herein, we have shown that differences between the frequencies of DNA damage-associated recombination in the *rad9* mutant and wild type depend on the identity and the concentration of the DNA damaging agent. Translocation and SCE frequencies were measured in strains containing truncated *his3* fragments, located either on chromosomes II and IV, or located in tandem on chromosome IV, respectively. DNA damage-associated frequencies of translocations after exposure to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), bleomycin, phleomycin, cisplatin, and camptothecin are higher in the *rad9* diploid than in wild type. However, translocation frequencies after exposure to 4-nitroquinoline 1-oxide (4-NQO) and *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG) are similar in *rad9* and wild-type strains. We suggest that the deficiency in triggering G<sub>2</sub> arrest after exposure to specific DNA damaging agents results in the higher levels of DNA damage-associated translocations in *rad9* mutants.

### Keywords

Recombination; DNA damaging agent; Yeast; G<sub>2</sub> checkpoint

## 1. Introduction

Cell cycle checkpoints may reduce chromosomal instability by allowing time for DNA repair before replication or segregation of chromatids. In *Saccharomyces cerevisiae* (yeast), four distinct cell cycle delays have been described: one G<sub>1</sub>/S phase, two S phase, and one G<sub>2</sub>/M phase [1]. Both single stranded DNA and stalled replication forks have been postulated to signal cell cycle checkpoints (for review, see [2]). Activation of one or more

<sup>\*</sup>Corresponding author. Tel.: +1-518-641-6467; fax: +1-518-641-6303, mfasullo@ordwayresearch.org (M. Fasullo).

cell cycle checkpoints may occur after cells are exposed to specific DNA damaging agents. For example, alkylating agents that methylate in the DNA minor groove may block DNA polymerase progression, while methylation in the major groove may be repaired by enzymes which indirectly produce DNA strand breaks [3]. Thus, how DNA damage is processed and whether the damage is sufficient to block DNA replication may be key factors in triggering particular checkpoints.

*RAD9* is required for cell cycle arrest in G<sub>2</sub> after exposure to DNA damaging agents [4]. DNA damaging agents that trigger cell cycle arrest in G<sub>2</sub> include UV and X rays [4], and chemical compounds that directly or indirectly cause double-strand breaks, such as hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) [5] and methyl methanesulfonate (MMS) [6]. Chemical compounds that cause intrastrand and interstrand cross-links, such as cisplatin [7], and topoisomerase I inhibitors, such as camptothecin [8], also trigger G<sub>2</sub> arrest. However, other DNA damaging agents which cause bulky adducts, such as the UV-mimetic agent 4-Nitroquinoline 1-oxide (4-NQO), do not trigger G<sub>2</sub> arrest in eukaryotic cells [9]. Thus, *RAD9*-mediated G<sub>2</sub> arrest can be triggered both by radiomimetic chemical agents, as well as specific chemical compounds which indirectly cause DNA single or double-strand breaks.

*RAD9*-mediated G<sub>2</sub> cell-cycle arrest allows more time for recombinational repair between sister chromatids, which are preferred substrates for X-ray-associated repair in yeast [10,11]. Consistent with this idea, *rad9* mutants exhibit lower frequencies of X-ray-associated SCEs but higher frequencies of X-ray-associated translocations [12]. When *rad9* cells are exposed to UV and MMS, there is only a minor decrease in frequencies of DNA damage-associated SCEs, compared to wild type [12]. These DNA damaging agents may generate a greater number of DNA lesions that trigger the *MEC1*-dependent S phase checkpoint to prevent replication fork collapse [13]. Thus, checkpoint mutants exposed to only a subset of DNA damaging agents exhibit higher frequencies of DNA damage-associated translocations and lower frequencies of DNA damage-associated SCE [12].

Besides its function to trigger cell cycle arrest in G<sub>2</sub>, *RAD9* is required to prevent mitosis when DNA replication is incomplete [14] and delaying entry into S phase after exposure either to ionizing radiation, UV, or 4-NQO [15]. *RAD9* is required to repair chromosome breaks that occur during S phase as a consequence of defective topoisomerase action [16] and in DNA damage tolerance mechanisms in excision repair mutants [17]. *rad9* mutants are defective in maintaining large yeast artificial chromosomes (YACs) when such YACs contain only one replication origin [18]. Thus, *RAD9* maintains genetic stability by triggering delays at other stages in the cell cycle.

In this manuscript, we have exposed cells to DNA damaging agents to identify compounds that stimulate more translocations but fewer SCEs in *rad9* mutants, compared to wild type. In addition to DNA damaging agents that directly cause strand breaks, we also chose cross-linking and alkylating agents and agents that cause bulky adducts. Compared to wild type, we observed more DNA damage-associated translocations when *rad9* cells were exposed to particular X-ray-mimetic agents, cisplatin or camptothecin but not to 4-NQO and MNNG.

## 2. Materials and methods

### 2.1. Strains and media

Standard media, including YPD (yeast extract, peptone, dextrose), synthetic complete lacking histidine (SC-HIS) have been previously described [19]. The strains used to measure homology-directed translocations and sister chromatid exchange (SCE) are listed in Table 1, and their construction was previously described [12]. These strains contain two truncated fragments of *his3*, *his3-3'* and *his3-5'* [12], as illustrated (Fig. 1). Directed translocations were measured in diploids, which were derived from one haploid containing the *his3* fragments and one haploid lacking the truncated fragments.

### 2.2. DNA damaging agents

Compounds used in this study included methyl methanesulfonate (MMS), *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG), cisplatin, 4-nitroquinoline 1-oxide (4-NQO), bleomycin, phleomycin, H<sub>2</sub>O<sub>2</sub>, camptothecin. H<sub>2</sub>O<sub>2</sub> (30% w/w) was purchased from Sigma. Chemicals were purchased from Sigma or Aldrich Chemicals. Chemicals were dissolved in either dimethyl sulfoxide (DMSO), dimethyl formamide (DMF) or water, depending on the specifications provided by the vendor.

### 2.3. Plate test assay for induced recombination in *rad9* diploids

A single colony from the appropriate strain was inoculated in YPD medium and incubated at 30 °C with agitation. Approximately 10<sup>7</sup> cells were then plated on SC-HIS plates and the indicated amounts of the chemical were added in the center of the plate. The zone of toxicity is indicative of the lethality of the chemical, while a halo of induced His<sup>+</sup> colonies is indicative of translocation events. Concentrations of solutions added to plates included H<sub>2</sub>O<sub>2</sub> (30% w/w), 10.5 M MMS, 100 mM MNNG, 140 mM 4-NQO, 133 mM cisplatin, 10 mg/ml camptothecin, 3 units/ml bleomycin, 10 mM phleomycin.

### 2.4. Culturing and treatment of yeast

Protocols used to test the recombinogenicity of chemical DNA damaging agents have been described [20]. For measuring stimulation of SCE and translocations, cells were pre-incubated for 30 min in YPD after treatment with the DNA damaging agent, washed twice with sterile H<sub>2</sub>O, and then plated on selective medium (SC-HIS). We exposed cells to concentrations of chemicals that exhibit equivalent levels of lethality in both wild-type and *rad9* strains (Table 2). Because spontaneous frequencies of translocations are significantly higher in *rad9* mutants, we also measured net frequencies of DNA damage-associated recombination by subtracting the spontaneous frequency from the frequency obtained after chemical exposure, as done previously [12,21,22]. At least three independent experiments were done for each DNA damaging agent. The significance of the differences between *rad9* mutants and *RAD9*<sup>+</sup> strains was determined using the two-tailed paired sample *t*-test [23].

## 2.5. CHEF gels

Electrophoretic karyotypes of His<sup>+</sup> recombinants were determined by pulse field electrophoresis using contour clamped gel electrophoresis (CHEF) to resolve chromosomal DNA. The running time was 26 h at 250 V (6 V/cm) and the pulse time was 90 s [22].

## 3. Results

### 3.1. Recombination assays

Our goal was to identify chemical DNA damaging agents that stimulate more translocations in *rad9* mutants, compared to wild type. Considering that *rad9* mutants are defective in X-ray-associated SCE [12], we then asked whether the frequencies of DNA damage-associated SCE were lower in *rad9* mutants after exposure to these chemical agents. To measure frequencies of DNA damage-associated translocation and SCE, we select His<sup>+</sup> prototrophs that result from recombination between the *his3* fragments located on chromosomes II and IV or located in tandem at the *trp1* locus, respectively. The rate of spontaneous translocations in the *rad9* diploid YB134 is  $2 \times 10^{-7}$ , which is fourfold higher than the rate in the wild-type diploid YB110 [12]. The rates of spontaneous SCE in *rad9* haploid and diploid mutants and in wild-type haploid and diploid strains are the same,  $\sim 2 \times 10^{-6}$  [12].

We employed a simple plate assay to detect recombinants that result from exposure to DNA damaging agents [20]. Because spontaneous rates of translocations are low [12,20], DNA damage-associated His<sup>+</sup> recombinants containing translocations appear as halos after a chemical compound is diffused from the center of a SC-HIS plate inoculated with either wild-type or *rad9* cells (Fig. 2). This assay indicates when there are more stimulated His<sup>+</sup> recombinants per total number of inoculated cells after exposure to the DNA damaging agent. We observed a thicker halo of stimulated His<sup>+</sup> recombinants and more spontaneous His<sup>+</sup> recombinants after *rad9* cells were exposed to MMS and H<sub>2</sub>O<sub>2</sub>, compared to wild type (Fig. 2). Other DNA damaging agents, including bleomycin, phleomycin, camptothecin and cisplatin, did not stimulate more His<sup>+</sup> recombinants using this plate assay (data not shown). However, as shown in previous studies [20], particular DNA damaging agents stimulate more recombination in log phase cell cultures.

### 3.2. Agents that directly cause DNA strand breaks stimulate more recombination in *rad9* mutants

We had previously shown that *rad9* cells exhibit higher frequencies of translocations after exposure to MMS [12], an agent known to promote DNA breaks. Actively growing log phase cultures of both wild-type and *rad9* diploid strains were then exposed to other DNA damaging agents that create single and double-strand breaks. Exposure to 2 mM H<sub>2</sub>O<sub>2</sub> increased translocation frequencies in both *RAD9* and *rad9* diploid strains by 31- and 22-fold, respectively; however, compared to wild type, there was a three-fold difference in the net frequency of DNA damage-associated translocations in the *rad9* diploid compared to the *RAD9* strain. Bleomycin and phleomycin exposure increased translocation frequencies 11- and 33-fold in the *rad9* diploid, and we observed an eight and fivefold difference in the net translocation frequencies, respectively, in *rad9* diploid compared to wild type. The higher frequencies of DNA damage-associated translocations obtained after exposure

of *rad9* cells to bleomycin, compared to the related compound phleomycin, may result from the higher number of double-strand breaks that are caused by bleomycin [24]. Thus, exposure to chemical agents that cause DNA strand breaks, including H<sub>2</sub>O<sub>2</sub>, bleomycin, and phleomycin, results in higher translocation frequencies in *rad9* than in wild-type (Table 2).

### 3.3. Camptothecin and cross-linking agents that trigger G<sub>2</sub> arrest stimulate more homology-directed translocations in *rad9* mutants

DNA damaging agents, including cross-linking agents and topoisomerase inhibitors, do not directly induce single and double-strand breaks but can trigger G<sub>2</sub> arrest in budding yeast. Exposure to 1.3 mM cisplatin increased translocation frequencies 81- and 22-fold in wild-type and *rad9* strains, respectively; net frequencies were threefold higher in *rad9* cells (Table 2). Net frequencies of camptothecin-associated translocations were fivefold higher in *rad9* cells, compared to wild type, although we observed more modest increases in DNA damage-associated frequencies of translocations after camptothecin exposure compared to other compounds. These results indicate that frequencies of DNA damage-associated translocations may be higher in checkpoint mutants after exposure to compounds that do not directly induce strand breaks.

### 3.4. DNA damage-associated SCE is decreased in *rad9* mutants after exposure to a subset of DNA damaging agents

To determine whether higher frequencies of DNA damage-associated translocations correlated with lower frequencies of DNA damage-associated SCE, we measured SCE frequencies in both wild-type (YB163 and YB146) and *rad9* (YB147) strains after exposure to H<sub>2</sub>O<sub>2</sub>, camptothecin, phleomycin, cisplatin and 4-NQO. After exposure to phleomycin and camptothecin, we observed significant twofold increases in SCE frequencies in wild type ( $P < 0.05$ ) but not in the *rad9* strain ( $P > 0.05$ ) (Table 3). SCE frequencies after exposure to bleomycin and cisplatin were  $4.7 \times 10^{-5}$  (average,  $n = 3$ ) and  $3.2 \times 10^{-5}$  (average,  $n = 3$ ) but not higher than wild type (YB147),  $2.4 \times 10^{-5}$  ( $P > 0.05$ ). We observed a fourfold stimulation of recombination in both wild-type and *rad9* cells after exposure to H<sub>2</sub>O<sub>2</sub> (Table 3) and 4-NQO (data not shown). Thus, differences in SCE recombination frequencies in wild type and *rad9* mutants after exposure to DNA damaging agents was only observed for a subset of DNA damaging agents.

### 3.5. RAD9 checkpoint is less efficient in suppressing 4-NQO and MNNG-associated recombination

Several DNA damaging agents create particular DNA adducts that require replication to initiate recombination, while other DNA damaging agents more frequently form DNA adducts in replicating regions. For example, recombinogenicity of 4-NQO is enhanced when cells undergo replication [25] and DNA adducts formed after MNNG exposure occur most frequently in active replicating regions [26]. We observed a 43- and 23-fold increase in translocation frequencies after wild-type and *rad9* cells were exposed to 4-NQO, respectively (Table 2). We observed a 52- and 21-fold increase in translocation frequencies after wild-type and *rad9* cells were exposed to MNNG, respectively (Table 2). Net DNA damage-associated frequencies after exposure to either MNNG or 4-NQO were less than

twofold higher in *rad9*. This data suggest that *RAD9* poorly suppresses recombination that is either stimulated by MNNG or 4-NQO.

### 3.6. Electrophoretic karyotypes of DNA damage-associated His<sup>+</sup> recombinants

We previously observed that most spontaneous and radiation-associated His<sup>+</sup> recombinants from wild type contain reciprocal translocations, *CEN2*::IV and *CEN4*::II, while most His<sup>+</sup> recombinants from *rad9* contain one non-reciprocal translocation, *CEN2*::IV [12]. We therefore characterized the electrophoretic karyotypes of DNA damage-associated translocations that occurred after exposure to H<sub>2</sub>O<sub>2</sub> and camptothecin, DNA damaging agents that do not directly stimulate double-strand breaks (Fig. 3). We observed that four out of four H<sub>2</sub>O<sub>2</sub>-associated His<sup>+</sup> recombinants from the *rad9* strain contain only one non-reciprocal translocation, *CEN2*::IV. After exposure to camptothecin, we characterized the electrophoretic karyotype of six His<sup>+</sup> recombinants from the *rad9* strain and three from wild type. Of the His<sup>+</sup> recombinants from the *rad9* strain, we observed that four contain non-reciprocal translocations and two contain reciprocal translocations. We observed that one His<sup>+</sup> recombinant contained reciprocal translocations and two contained non-reciprocal translocations from the wild-type strain. This data suggest that DNA damage caused by camptothecin stimulates both reciprocal and non-reciprocal translocations.

## 4. Discussion

*S. cerevisiae rad9* mutants exhibit complex phenotypes, including radiation sensitivity, enhanced frequencies of chromosome loss, and failure to arrest the cell cycle in G<sub>2</sub> [15,17,18,27]. Here we report that, depending on the chemical compound, *RAD9* can partially suppress the frequencies of DNA damage-associated translocations and increase the frequencies of DNA damage-associated SCE. We observed higher frequencies of translocations in *rad9* mutants after exposure to DNA damaging agents that are known to specifically trigger cell cycle arrest in the G<sub>2</sub> phase, and these agents include bleomycin, phleomycin, H<sub>2</sub>O<sub>2</sub>, cisplatin and camptothecin. Since frequencies of DNA damage-associated SCE were the same in wild type and *rad9* after exposure to specific DNA damaging agents, we speculate that S phase checkpoints are important in enhancing recombinational repair. Because *rad9* and wild-type strains did not exhibit different recombination phenotypes after exposure to MNNG and 4-NQO but *rad9* mutants are hypersensitive to both MNNG and 4-NQO, we speculate that *RAD9* participates in additional DNA repair pathways to confer resistance both to alkylating compounds and compounds that cause bulky adducts.

The data supporting these conclusions was obtained using both a simple plate assay and a quantitative liquid assay. The plate assay provides a quick method to identify a subset of chemical compounds that stimulate more translocations in *rad9* mutants. However, the liquid assay provides a more accurate measurement of the translocation frequencies after exposure to particular DNA damaging agents, which are active in log phase cells or in the presence of oxygen. Although a subset of DNA damage-associated translocation frequencies are higher in *rad9* mutants than in wild type, the fold induction (ratio of the DNA damage-associated translocation frequency to the spontaneous frequencies) may be higher in wild type than in



the *rad9* mutant because the spontaneous translocation frequencies are lower in the wild-type strain.

We previously documented that frequencies of X-ray-associated translocations are increased but frequencies of X-ray-associated SCE are decreased in *rad9* mutants [12]. Particular DNA damaging agents that mimic the effects of ionizing radiation, such as phleomycin, thus stimulate more translocations but fewer SCEs in *rad9* mutants. We suggest that *RAD9* may confer resistance to several radiomimetic compounds by simply triggering a G<sub>2</sub> arrest and allowing more time for sister chromatid gap repair.

Higher frequencies of DNA damage-associated translocations in *rad9* cells after camptothecin and cisplatin exposure support ideas that both camptothecin [28] and cisplatin [7] create DNA adducts that indirectly generate recombinogenic double-strand breaks. Cisplatin-induced interstrand crosslinks creates replication-dependent double-strand breaks that trigger G<sub>2</sub> arrest [29]. Modest stimulation of SCE after cisplatin exposure could result from the low percentage of interstrand crosslinks among total number of DNA adducts [29] and the relatively high frequencies of spontaneous SCE.

Double-strand breaks resulting from camptothecin exposure occur when the DNA replication apparatus encounters trapped topoisomerase I intermediates, leading to replication fork collapse [16]. His<sup>+</sup> recombinants resulting from either unequal SCE or translocations after camptothecin exposure could result from break-induced replication (BIR) mechanisms [30,31], and *RAD9*-mediated G<sub>2</sub> arrest may provide time for unequal SCE. Non-reciprocal translocations are postulated to occur by BIR [22]. However, we detected both reciprocal and non-reciprocal translocations among camptothecin-associated His<sup>+</sup> recombinants. Considering that we exposed asynchronous log phase cell cultures to camptothecin, it is possible that camptothecin-associated DNA damage occurred after DNA replication was completed and gap repair mechanisms initiated recombination resulting in reciprocal translocations.

We observed that in *rad9* mutants, higher frequencies of DNA damage-associated translocations and lower frequencies of DNA damage-associated SCE do not correlate after exposure to particular DNA damaging agents, such as H<sub>2</sub>O<sub>2</sub>. Frequencies of MMS and UV-associated SCE are also similar in wild type and *rad9* mutants [12]. Both UV and MMS create DNA adducts that impede DNA replication fork progression and trigger S phase checkpoints [32], although longer MMS-induced S phase has been also attributed to the inhibition of replication initiation at late replication origins [13]. Thus, it would be interesting to determine whether DNA damage-associated SCE was deficient in mutants defective in S phase checkpoints.

We found that *RAD9* does not function to suppress DNA damage-associated translocations after exposure to either 4-NQO or MNNG. Consistent with previous literature [26,33], we speculate that these compounds are recombinogenic in S phase, and *RAD9*-independent S phase checkpoints regulate DNA damage-associated recombination. The *RAD9* requirement for efficient UV excision repair [34] and for the G<sub>1</sub> cell cycle delay [15] after exposure to

DNA damaging agents may explain the sensitivity of *rad9* mutants to the UV-mimetic agent 4-NQO and to particular alkylating agents.

Our results are interesting to compare with those from a related study concerning the types of DNA damaging agents that stimulate gross chromosomal rearrangements [35]. The DNA damage-associated frequencies of translocations are higher than frequencies of gross chromosomal rearrangements, possibly reflecting the greater efficiency of homologous recombination, compared to non-homologous recombination. DNA damage resulting from X-rays and bleomycin exposure, generate more gross chromosomal rearrangements than DNA damaging agents that do not directly cause double-strand breaks. However, our results indicate that a subset of alkylating agents and bulky adducts are potent stimulators of chromosomal rearrangements directed by homologous recombination. Although there are several reasons that may account for these differences, it is interesting to note that the *RAD9* checkpoint suppresses directed translocations; whereas, the S phase checkpoint is important in suppressing gross chromosomal rearrangements [36]. Thus, it will be interesting to extend these studies and determine whether *RAD9*-independent S phase checkpoints also suppress homology-directed translocations.

## Acknowledgements

This research was supported by grant CA70105 from the National Institutes of Health. We thank Cinzia Cera for carefully reading this manuscript.


## References

- [1]. Weinert T, DNA damage checkpoints update: getting molecular, *Curr. Opin. Genet. Dev* 8 (1988) 183–185.
- [2]. Nyberg K, Michelson R, Putnam C, Weinert TA, Toward maintaining the genome: DNA damage and replication checkpoints, *Ann. Rev. Genet* 36 (2002) 617–657. [PubMed: 12429704]
- [3]. Friedberg EC, Walker GC, Siede W, DNA Repair and Mutagenesis, ASM Press, Washington DC, 1995.
- [4]. Weinert TA, Hartwell LH, The *RAD9* gene controls the cell cycle response to DNA damage in *Saccharomyces cerevisiae*, *Science* 241 (1988) 317–322. [PubMed: 3291120]
- [5]. Flattery-O'Brien JA, W Dawes I, Hydrogen peroxide causes *RAD9*-dependent cell cycle arrest in G2 in *Saccharomyces cerevisiae* whereas menadione causes G1 arrest independent of *RAD9* function, *J. Biol. Chem* 273 (1998) 8564–8571. [PubMed: 9535829]
- [6]. Kupiec M, Simchen G, Arrest of the mitotic cell cycle and of meiosis in *Saccharomyces cerevisiae* by MMS, *Mol. Gen. Genet* 201 (1985) 558–564.
- [7]. Grossman KF, Brown J, Moses RE, Cisplatin DNA cross-links do not inhibit S-phase and cause only a G2/M arrest in *Saccharomyces cerevisiae*, *Mutat. Res* 434 (1999) 29–39. [PubMed: 10377946]
- [8]. Levin NA, Bjornsti MA, Fink GR, A novel mutation in DNA topoisomerase I of yeast causes DNA damage and *RAD9*-dependent cell cycle arrest, *Genetics* 133 (1993) 799–814. [PubMed: 8385050]
- [9]. Levin P, Escalza P, Mateos S, Cortes F, Mitomycin C, 4-nitroquinoline-1-oxide and ethyl methanesulfonate induce long-lived lesions in DNA which result in SCEs during successive cell cycles in human lymphocytes, *Mutat. Res* 270 (1992) 177–183. [PubMed: 1383734]
- [10]. Fabre F, Boulet A, Roman H, Gene conversion at different points in the mitotic cycle of *Saccharomyces cerevisiae*, *Mol. Gen. Genet* 195 (1984) 139–143. [PubMed: 6387388]




- [11]. Kadyk LC, Hartwell LH, Sister chromatids are preferred over homologs as substrates for recombinational repair in *Saccharomyces cerevisiae*, *Genetics* 132 (1992) 387–402. [PubMed: 1427035]
- [12]. Fasullo M, Bennett T, AhChing P, Koudelik J, The *Saccharomyces cerevisiae* *RAD9* checkpoint reduces the DNA damage-associated stimulation of directed translocations, *Mol. Cell. Biol* 18 (1998) 1190–1200. [PubMed: 9488434]
- [13]. Tercero JA, Diffley JF, Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint, *Nature* 412 (2001) 553–557. [PubMed: 11484057]
- [14]. Garvick B, Carson M, Hartwell L, Single-stranded DNA arising at telomeres in *cdc13* mutants may constitute a specific signal for the *RAD9* checkpoint, *Mol Cell Biol*. 15, 6128–6138. [PubMed: 7565765]
- [15]. Siede W, Friedberg A, Friedberg E, *RAD9*-dependent G1 arrest defines a second checkpoint for damaged DNA in the cell cycle of *Saccharomyces cerevisiae*, *Proc. Nat. Acad. Sci. USA* 90 (1993) 7985–7989. [PubMed: 8367452]
- [16]. Pouliot JJ, Robertson CA, Nash HA, Pathways for repair of topoisomerase I covalent complexes in *Saccharomyces cerevisiae*, *Genes Cells* 6 (2001) 677–687. [PubMed: 11532027]
- [17]. Paulovich AG, Armour CD, Hartwell LH, The *Saccharomyces cerevisiae* *RAD9*, *RAD17*, *RAD24* and *MEC3* genes are required for tolerating irreparable, ultraviolet-induced DNA damage, *Genetics* 150 (1998) 75–93. [PubMed: 9725831]
- [18]. Van Brabant A, Buchanan C, Charboneau E, Fangman W, Brewer B, An origin-deficient yeast artificial chromosome triggers a cell cycle checkpoint, *Mol. Cell* 7 (2001) 705–713. [PubMed: 11336695]
- [19]. Sherman F, Fink GR, Hicks JB, Appendix A, in: *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1986, pp. 163–168.
- [20]. Fasullo M, Dave P, Rothstein R, DNA-damaging agents stimulate the formation of directed reciprocal translocations in *Saccharomyces cerevisiae*, *Mutat. Res* 314 (1994) 121–133. [PubMed: 7510362]
- [21]. Fasullo M, P Dave, Mating-type regulates the DNA damage-associated stimulation of reciprocal translocation events in *Saccharomyces cerevisiae*, *Mol. Gen. Genet* 243 (1994) 63–70. [PubMed: 8190072]
- [22]. Fasullo M, Giallanza P, Dong Z, Cera C, Bennett T, *Saccharomyces cerevisiae* *rad51* mutants are defective in DNA damage-associated sister chromatid exchanges but exhibit increased rates of homology directed translocations, *Genetics* 158, 959–972. [PubMed: 11454747]
- [23]. Zar JH, *Biostatistical Analysis*, Prentice Hall, Englewood Cliffs, NJ, 1996.
- [24]. McKoy JF, P. Pleninger L Wall A Pramanik M Martinez BW Morre, Genetic changes and bioassays in bleomycin- and phleomycin-treated cells, and their relationship to chromosomal breaks, *Mutat. Res* 336 (1995) 19–27. [PubMed: 7528892]
- [25]. Galli A, Schiestl RH, Cell division transforms mutagenic lesions into deletion-recombinogenic lesions in yeast cells, *Mutat. Res* 429 (1999) 13–26. [PubMed: 10434021]
- [26]. Burke W, Fangman WL, Temporal order in yeast chromosome replication, *Cell* 5 (1975) 263–269. [PubMed: 1097124]
- [27]. Aboussekhra A, Vialard JE, Morison D, Torr-Ruiz MA, Cernakova L, Fabre F, Lowndes N, The novel role for the budding yeast *RAD9* checkpoint gene in DNA damage-dependent transcription, *EMBO J*. 14 (1996) 3912–3922.
- [28]. Nitiss J, Wang J, DNA topoisomerase-targeting antitumor drugs can be studied in yeast, *Proc. Natl. Acad. Sci. USA* 85 (1998) 7501–7505.
- [29]. Grossman KF, Ward A, Moses RE, *Saccharomyces cerevisiae*. Lacking *Snm1*, *Rev3*, or *Rad51* have a normal S-phase but arrest permanently in G2 after cisplatin treatment, *Mutat. Res* 461 (2000) 1–13. [PubMed: 10980408]
- [30]. Malkova A, Ivanov EL, Haber JE, Double-strand break repair in the absence of *RAD51* in yeast: a possible role for break-induced DNA replication, *Proc. Natl. Acad. Sci. USA* 93 (1996) 7131–7136. [PubMed: 8692957]
- [31]. Haber JE, DNA recombination: the replication connection, *Trends Biochem. Sci* 24 (1999) 271–275. [PubMed: 10390616]


- [32]. Foiani M, Gerrari M, Liberi G, Lopes M, Lucca C, Marini F, Pelliccioli A, Muzi Falconi M, P. Plevani S S-phase DNA damage checkpoint in budding yeast, *J. Biol. Chem* 379 (1999) 1019–1023.
- [33]. Romotar R, Belanger E, Brodeur I, Masson JY, Drobetsky EA, A yeast homologue of the human phosphotyrosyl phosphatase activator PTPA is implicated in protection against oxidative DNA damage induced by the model carcinogen 4-nitroquinoline 1-oxide, *J. Biol. Chem* 273 (1998) 21489–21496. [PubMed: 9705277]
- [34]. Al-Mograbi NM, Al-Sharif IS, Aboussekhra A, The *Saccharomyces cerevisiae* *RAD9* cell cycle checkpoint gene is required for optimal repair of UV-induced pyrimidine dimers in both G(1) and G(2)/M phases of the cell cycle, *Nucleic Acids Res.* 29 (2001) 2020–2025. [PubMed: 11353070]
- [35]. Myung K, Kolodner R, Induction of genome instability by DNA damage in *Saccharomyces cerevisiae*, *DNA Rep.* 2 (2003) 243–258.
- [36]. Kolodner R, Putnam C, Myung K, Maintenance of genome stability in *Saccharomyces cerevisiae*, *Science* 297 (2002) 552–557. [PubMed: 12142524]

**Fig. 1.**

Recombination assays used in this study. Ovals represent centromeres and lines represent chromosomes. For simplicity, the left arms of chromosomes are not included. The position and orientation of the *his3* recombinational substrates are shown as present in strains used to measure (A) reciprocal translocations and (B) unequal SCE. An "X" designates potential sites of crossovers, and the resulting chromosomal rearrangement is presented. An arrow and feathers denote *HIS3*. As indicated on the bottom of the figure, the 5' deletion lacks the feathers and the 3' deletion lacks the arrow. The two regions of sequence identity shared by the *his3* fragments are indicated by decorated boxes; broadly spaced diagonal lines indicate a region of ~300 bp, and tightly spaced diagonal lines indicate a region of 167 bp.



**Fig. 2.** Plate assay demonstrating higher levels of DNA damage-associated translocations in a *rad9* diploid compared to a wild-type diploid. (A) YB110 (wild-type diploid) + 0.2  $\mu$ l of MMS. (B) YB110 (wild-type diploid) + 1  $\mu$ l of  $H_2O_2$ . (C) YB134 (*rad9* mutant) + 0.2  $\mu$ l of MMS. (D) YB134 (*rad9* mutant) +  $\mu$ l of  $H_2O_2$ .



**Fig. 3.** Electrophoretic karyotype of camptothecin-associated His<sup>+</sup> recombinants generated in the *rad9* diploid YB134. (A) YB134 His<sup>-</sup>-parent. (B) His<sup>+</sup> recombinant containing a non-reciprocal translocations. (C) His<sup>+</sup> recombinant containing a reciprocal translocation. (D) His<sup>+</sup> recombinant containing a reciprocal translocation. The positions of chromosomes II, IV, and translocations *CEN2*:: IV and *CEN4*:: V are indicated by the arrow.

**Table 1**

Yeast strains

Laboratory name	Genotype <sup>a</sup>	Source
YA102	<i>MAIaur3-52, his3-200, ade2-101, lys2-801, trp1-1, gal3-</i>	M. Carlson
YB109	<i>MATa leu2-3,112,GAL1::his3-5',trp1::his3-3'::HOcs, lys2'</i> (leaky)	This laboratory
YB130	<i>MATarad9::URA3</i>	This laboratory
YB132	<i>MATa leu2-3,112, GAL1::his3-5',trp1::his3-3'::HOcs, lys2'</i> (leaky), <i>rad9::URA3</i>	This laboratory
YB110	YB109 × YA102	This laboratory
YB134	YB130 × YB132	This laboratory
YB163	<i>MATa-inctrp1::[his3-3'::HOcs, his3-5']</i>	This laboratory
YB146	<i>MATa trp1::[his3-3'::HOcs, his3-5']</i>	This laboratory
YB147	<i>MATa trp1::[his3-3'::HOcs, his3-5'] rad9::URA3</i>	This laboratory

<sup>a</sup>Genotype the same as YA102 unless indicated.



**Table 2**

Stimulation of translocations by DNA damaging agents in *RAD9* (YB110) and the *rad9*::*URA3* diploid (YB134)

Agent (concentration or dose)	Stimulation in <i>RAD9</i> (YB110) <sup>d</sup>		Stimulation in <i>rad9</i> <sup>-</sup> (YB134) <sup>d</sup>		Ratio <sup>c</sup>
	His <sup>+</sup> /CFU × 10 <sup>7</sup> (survival%)	Net <sup>b</sup>	His <sup>+</sup> /CFU × 10 <sup>7</sup> (survival%)	Net <sup>b</sup>	
Spontaneous	6 ± 2	0	23 ± 14	0	NA
<b>Alkylating agents<sup>d</sup></b>					
MMS 0.1% (10.5 mM)	62 ± 16(94)	59 ± 13	248 ± 24(81)	246 ± 21	4.2
MNNG 50 (µM)	100 ± 9 (88)	92 ± 1	173 ± 46 (90)	153 ± 38	1.7
MNNG 100 (µM)	250 ± 10 (85)	248 ± 11	347 ± 40 (76)	326 ± 37	1.3
MNNG 200 (µM)	345 ± 38 (53)	338 ± 21	306 ± 62 (16)	253 ± 43	0.7
<b>Bulky adducts</b>					
4-NQO 1 (µM)	28 ± 9 (100)	27 ± 14	43 ± 6 (100)	33 ± 10	1.2
4-NQO 10 (µM)	494 ± 163(67)	484 ± 160	666 ± 91 (47)	636 ± 96	1.3
Cisplatin 1.3 (µM)	122 ± 33 (100)	120 ± 25	347 ± 71(87)	330 ± 70	2.8
<b>Free radical agents</b>					
Bleomycin 0.015 units	60 ± 52 (94)	54 ± 52	446 ± 130(86)	403 ± 136	7.5
Phleomycin 10 (µM)	67 ± 31(93)	59 ± 31	295 ± 117 (60)	286 ± 116	4.8
H <sub>2</sub> O <sub>2</sub> 2 (µM)	219 ± 92 (76)	212 ± 92	585 ± 259 (76)	558 ± 260	2.6
H <sub>2</sub> O <sub>2</sub> 4 (µM)	346 ± 138(71)	329 ± 192	533 ± 167 (54)	523 ± 165	1.6
<b>TopoI inhibitor</b>					
Camptothecin 50 (µg/ml)	5 ± 5 (95)	<1	38 ± 14 (99)	26 ± 14	5.2
Camptothecin 100 (µg/ml)	34 ± 7 (95)	33 ± 7	163 ± 50 (85)	153 ± 54	4.6

<sup>a</sup>For complete genotype, see Table 1.

<sup>b</sup>Net stimulation = (His<sup>+</sup> frequency w/agent – His<sup>+</sup> spontaneous frequency) × 10<sup>7</sup>; N > 3.

<sup>c</sup>(Net His<sup>+</sup> per 10<sup>7</sup> CFU for *rad9*<sup>-</sup>)/(Net His<sup>+</sup> per 10<sup>7</sup> CFU for *RAD9*<sup>+</sup>); NA, not applicable.

<sup>d</sup>DNA damage-associated frequencies for MMS were previously published, see [12].

**Table 3**  
Stimulation of SCE by H<sub>2</sub>O<sub>2</sub>, camptothecin, and phleomycin in *RAD9* and *rad9*::*URA3* strains

Chemical agent	Stimulation in <i>RAD9</i> (YB163) <sup>a</sup>		Stimulation in <i>rad9</i> :: <i>URA3</i> (YB147)	
	His <sup>+</sup> /CFU × 10 <sup>6</sup> (survival %)	Fold increase <sup>b</sup>	His <sup>+</sup> /CFU × 10 <sup>6</sup> (survival %)	Fold increase <sup>b</sup>
Spontaneous	16 ± 2 (100)	1	15 ± 2 (100)	1
0.04% H <sub>2</sub> O <sub>2</sub>	59 ± 12 (40)	3.7	60 ± 20 (35)	4
50 µg/ml camptothecin	32 ± 7 (88)	2	20 ± 3 (91)	1.3
10 µM phleomycin	33 ± 6 (41)	2.1	17 ± 3 (45)	1.1

<sup>a</sup>For complete genotype, see Table 1.

<sup>b</sup>His<sup>+</sup> frequency with agent/spontaneous His<sup>+</sup> frequency.